The parity paradigm: Can legislation help reduce the cost burden of oral anticancer medications?

Sheetal M. Kircher*, Caitlin R. Meeker, Halla Nimeiri, Daniel M. Geynisman, S. Yousuf Zafar, Veena Shankaran, Jonas De Souza, Yu Ning Wong

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Over the last decade, there has been increased development and use of oral anticancer medications, which sometimes leads to high cost sharing for patients. Drug parity laws require insurance plans to cover oral anticancer medications with the same cost sharing as intravenous/injected chemotherapy or have a capped limit on out-of-pocket costs. There are currently 36 enacted state laws (plus the District of Columbia) addressing drug parity, but no federal laws. In this policy perspective piece, we discuss the history, opportunities, and limitations of drug parity laws in oncology. We also discuss the implications of provisions of the Affordable Care Act and other proposed policy reforms on financing oral chemotherapy.

Original languageEnglish (US)
Pages (from-to)88-98
Number of pages11
JournalValue in Health
Volume19
Issue number1
DOIs
StatePublished - Jan 1 2016

Keywords

  • drug costs
  • neoplasms

ASJC Scopus subject areas

  • Health Policy
  • Public Health, Environmental and Occupational Health

Fingerprint Dive into the research topics of 'The parity paradigm: Can legislation help reduce the cost burden of oral anticancer medications?'. Together they form a unique fingerprint.

Cite this